Ultragenyx Pharmaceutical (RARE) remains a Sell after its Phase 3 OI program failed to meet primary fracture reduction endpoints, eroding its key growth narrative. RARE's financials are stressed, with ...

Melanie Watson Bernhardt had this way of lighting up a room, even after her condition. She grabbed hearts back in the 80s as Kathy Gordon on Diff'rent Strokes, Arnold's buddy in four sweet episodes.

Neither study achieved its primary endpoint of reduction in annualized clinical fracture rate compared to placebo (ORBIT) or bisphosphonates (COSMIC) Both studies achieved secondary endpoint of ...

LONDON - Mereo BioPharma Group plc (NASDAQ:MREO) announced Monday that its Phase 3 ORBIT and COSMIC studies for setrusumab in osteogenesis imperfecta (OI) failed to achieve their primary endpoints of ...

NOVATO, Calif., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced results from the Phase 3 Orbit and Cosmic studies for setrusumab (UX143) in Osteogenesis ...

Shares of Ultragenyx Pharmaceutical RARE and Mereo BioPharma MREO plunged 42.3% and 87.6%, respectively, on Dec. 29 after the companies announced disappointing data from the phase III Orbit and Cosmic ...

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) and Mereo BioPharma Group plc (NASDAQ: MREO) stocks hit their 52-week low on Monday, as per data from Benzinga Pro. Mereo BioPharma and its partner ...

Ultragenyx Pharmaceutical has reported the failure of a pair of late-phase brittle bone disease trials, prompting the biotech to prepare to significantly reduce its spending. The studies tested the ...